Complete Response to Pembrolizumab in Radiation-Induced Undifferentiated Pleomorphic Sarcoma of the Face: A Case Report and Review of the Literature.

IF 0.7 Q4 ONCOLOGY

Case Reports in Oncology Pub Date : 2026-06-30 eCollection Date: 2026-01-01 DOI:10.1159/000552848

Ethan Roman Leoni, Victor Lin, Caroline Bonaventure, Sagar Kansara

{"title":"Complete Response to Pembrolizumab in Radiation-Induced Undifferentiated Pleomorphic Sarcoma of the Face: A Case Report and Review of the Literature.","authors":"Ethan Roman Leoni, Victor Lin, Caroline Bonaventure, Sagar Kansara","doi":"10.1159/000552848","DOIUrl":null,"url":null,"abstract":"Introduction: Undifferentiated pleomorphic sarcoma (UPS) as a secondary malignancy following adjuvant radiation therapy is rare and typically associated with poor prognosis. PD-1 inhibition has been previously investigated as a possible treatment in this space.Case presentation: This case presents a 91-year-old male with UPS of the right parotid region, presumed secondary to radiation therapy for cutaneous squamous cell carcinoma. The patient was treated with pembrolizumab immunotherapy and a complete clinical response was achieved, with significant improvement noted on restaging scans. Treatment was well-tolerated despite advanced age and multiple comorbidities.Conclusion: This case demonstrates the efficacy of PD-1 inhibitor therapy in radiation-induced UPS and supports emerging evidence for immunotherapy as a viable treatment option in advanced or unresectable sarcomas, particularly with patients who cannot undergo surgery.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1130-1137"},"PeriodicalIF":0.7000,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13450989/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000552848","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Undifferentiated pleomorphic sarcoma (UPS) as a secondary malignancy following adjuvant radiation therapy is rare and typically associated with poor prognosis. PD-1 inhibition has been previously investigated as a possible treatment in this space.

Case presentation: This case presents a 91-year-old male with UPS of the right parotid region, presumed secondary to radiation therapy for cutaneous squamous cell carcinoma. The patient was treated with pembrolizumab immunotherapy and a complete clinical response was achieved, with significant improvement noted on restaging scans. Treatment was well-tolerated despite advanced age and multiple comorbidities.

Conclusion: This case demonstrates the efficacy of PD-1 inhibitor therapy in radiation-induced UPS and supports emerging evidence for immunotherapy as a viable treatment option in advanced or unresectable sarcomas, particularly with patients who cannot undergo surgery.

查看原文本刊更多论文

派姆单抗治疗放射诱导的面部未分化多形性肉瘤的完全缓解：1例报告和文献回顾。

未分化多形性肉瘤（UPS）作为辅助放射治疗后的继发性恶性肿瘤是罕见的，通常与预后不良有关。PD-1抑制曾作为一种可能的治疗方法在这一领域进行过研究。病例介绍：本病例为91岁男性，右腮腺区UPS，推测继发于皮肤鳞状细胞癌放射治疗。患者接受了派姆单抗免疫治疗，获得了完全的临床反应，重新扫描显示有显著改善。尽管年龄较大且有多种合并症，但治疗耐受性良好。结论：该病例证明了PD-1抑制剂治疗放射诱导的UPS的有效性，并支持了免疫治疗作为晚期或不可切除肉瘤的可行治疗选择的新证据，特别是对于不能接受手术的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊